# A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) for the Treatment of Alzheimer's Disease

> **NCT04228666** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Hope Biosciences LLC**

## Conditions studied

- Alzheimer Disease

## Interventions

- **BIOLOGICAL:** HB-adMSCs

## Key facts

- **NCT ID:** NCT04228666
- **Lead sponsor:** Hope Biosciences LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-03-01
- **Primary completion:** 2022-02-01
- **Final completion:** 2022-02-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Due to COVID 19 Pandemic
- **Last updated:** 2025-09-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04228666

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04228666, "A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) for the Treatment of Alzheimer's Disease". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04228666. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*